Novel adenoviral gene delivery system targeted against head and neck cancer

Laryngoscope

Volumn 118, Issue 4, 2008, Pages 650-658

  Li, Daqing ^a,c   Guang, Wei ^a   Abuzeid, Waleed M ^a   Roy, Soumitra ^a   Gao, Guang Ping ^a   Sauk, John J ^b   O'Malley Jr , Bert W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Clinical Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HEAT SHOCK PROTEIN 47;

ARTICLE; CANCER GENE THERAPY; CELL SURFACE; CONTROLLED STUDY; DRUG SYNTHESIS; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, VIRAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEAD AND NECK NEOPLASMS; HSP47 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUMINESCENT AGENTS; TARGETED GENE REPAIR; TRANSFECTION; TRANSGENES; TUMOR MARKERS, BIOLOGICAL; VIRUS ATTACHMENT;

EID: 41849136910     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e3181613aba     Document Type: Article

References (34)

1. ACS. Cancer Facts and Figures 2006. Atlanta: American Cancer Society, 2006.
2. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-1900.
3. Li D, Duan L, Freimuth P, O'Malley BW Jr. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999;5:4175-4181.
4. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999;5:1715-1722.
5. Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents [Review]. Int J Oncol 2002;21:1161-1174.
6. Flotte TR. Gene therapy: the first two decades and the current state-of-the-art. J Cell Physiol 2007;213:301-305.
7. Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol 2006;2:137-143.
8. Curiel DT. Strategies to adapt adenoviral vectors for targeted delivery. Ann N Y Acad Sci 1999;886:158-171.
9. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998;72:1844-1852.
10. Jee YS, Lee SG, Lee JC, et al. Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. Anticancer Res 2002;22:2629-2634.
11. Stevenson SC, Rollence M, Marshall-Neff J, McClelland A. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 1997;71:4782-4790.
12. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996;70:6839-6846.
13. Sauk JJ, Coletta RD, Norris K, Hebert C. Binding motifs of CBP2 a potential cell surface target for carcinoma cells. J Cell Biochem 2000;78:251-263.
14. Tasab M, Batten MR, Bulleid NJ. Hsp47: a molecular chaperone that interacts with and stabilizes correctly-folded procollagen. EMBO J 2000;19:2204-2211.
15. Hebert C, Norris K, Della CR, Reynolds M, Ordonez J, Sauk JJ. Cell surface colligin/Hsp47 associates with tetraspanin protein CD9 in epidermoid carcinoma cell lines. J Cell Biochem 1999;73:248-258.
16. Nagata K. Hsp47: a collagen-specific molecular chaperone. Trends Biochem Sci 1996;21:22-26.
17. Nagata K. Expression and function of heat shock protein 47: a collagen-specific molecular chaperone in the endoplasmic reticulum. Matrix Biol 1998;16:379-386.
18. Koide T, Asada S, Nagata K. Substrate recognition of collagen-specific molecular chaperone HSP47. Structural requirements and binding regulation. J Biol Chem 1999;274:34523-34526.
19. Koide T, Aso A, Yorihuzi T, Nagata K. Conformational requirements of collagenous peptides for recognition by the chaperone protein HSP47. J Biol Chem 2000;275:27957-27963.
20. Sauk JJ, Smith T, Norris K, Ferreira L. Hsp47 and the translation-translocation machinery cooperate in the production of alpha 1(I) chains of type I procollagen. J Biol Chem 1994;269:3941-3946.
21. Hebert C, Coletta RD, Norris K, Nikitakis N, Lopes M, Sauk JJ. Non-natural CBP2 binding peptides and peptomers modulate carcinoma cell adhesion and invasion. J Cell Biochem 2001;82:145-154.
22. Sauk JJ, Nikitakis N, Siavash H. Hsp47 a novel collagen binding serpin chaperone, autoantigen and therapeutic target. Front Biosci 2005;10:107-118.
23. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-1323.
24. Vokes EE, Athanasiadis I. Chemotherapy of squamous cell carcinoma of head and neck: the future is now. Ann Oncol 1996;7:15-29.
25. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-1586.
26. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:429-435.
27. Bossi G, Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 2007;29:272-284.
28. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000;18:609-622.
29. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11:2197-2205.
30. Hasenburg A, Tong XW, Fischer DC, et al. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol 2001;83:549-554.
31. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 2001;1:130-141.
32. Hemminki A, Belousova N, Zinn KR, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001;4:223-231.
33. Hemminki A, Zinn KR, Liu B, et al. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst 2002;94:741-749.
34. Hidaka C, Milano E, Leopold PL, et al. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest 1999;103:579-587.